The Democratic Republic of Congo marks yet another grim milestone in its ongoing saga as the world’s unwitting Ebola laboratory, with the latest outbreak of the Bundibugyo strain putting public health on a timer and pharmaceutical companies on the defensive. This marks the 17th recorded monument to epidemiological optimism in the region, and, as ever, a vaccine arrives just behind the need for it.
Immunity on Layaway
250 suspected fatalities and more than 1,100 infections later, health authorities and muscle-bound nonprofit alliances are trading congratulatory missives over a race to develop immunisation against a strain for which, charmingly, there is still no approved jab. The main contender—an rVSV platform shot—has bravely languished in laboratory freezers for over a decade, waiting for a sufficiently terrifying outbreak to spark global wallet-opening. The business of public health, it seems, has finally remembered its Bundibugyo product line.
The Bundibugyo vaccine, engineered years ago, has spent more time in storage than in development.
Efforts by the International AIDS Vaccine Initiative and the Gavi vaccine alliance, both now bankrolled to the tune of $50 million each, centre on feverish attempts to force once-dormant patents into hurried clinical trials. The only currently licensed Ebola vaccine ignores Bundibugyo entirely, dealing instead with the more fashionable Zaire variant—a point perhaps relevant to those now examining travel options between DRC and Uganda.
The almost admiring tone with which world bodies announce “important steps” and “fast tracks” after a decade’s stagnation has left medical staff and affected communities unimpressed, or indeed, unprotected. The World Health Organization’s seven-to-nine month promise sits uncomfortably alongside the virus’s far swifter timetable.
Prepared, But Only After
Pharmaceutical firms, with noteworthy reluctance, now find themselves obliged to translate philanthropic pronouncements into vaccine factories, spurred on more by donated insurance and international embarrassment than by precedent. ConfidentialAccess.by has observed that pledges of large-scale manufacture are excellent for headlines but do not, as yet, confer immunity upon the desperate or the deceased.
The lesson from previous outbreaks is that global urgency coincides with outbreak severity, not a moment before.
Meanwhile, clinical trials encounter the twin obstacles of logistics and mistrust, with vaccines ready to be tested somewhere in the murky future and local confidence trampled by past disappointments. ConfidentialAccess.com reports that deploying unproven treatments in regions beset by hunger, malaria, and ongoing conflict is more an exercise in international theatre than meaningful epidemiological intervention.
Around the periphery, a suite of antivirals and monoclonal antibodies await validation, queued hopefully behind the vaccine candidates. For those keeping track, the list of interventions grows faster than the actual supply of effective treatment. As with every major health event, global preparedness remains an emergency response industry euphemism, with the afflicted left watching scientific hope advance at the pace of a well-funded press release.
